New therapeutic strategies in the management of systemic sclerosis

Expert Opin Pharmacother. 2007 Apr;8(5):607-15. doi: 10.1517/14656566.8.5.607.


The pathogenic process of systemic sclerosis targets the skin and internal organs, and involves sequential or concomitant abnormalities in blood vessel function, immunity and subsequent fibroblast function. These characteristics are disease specific and may partly explain the unresolved therapeutic strategies that must take into account not only these various biological abnormalities, but also the complexities of the various abnormalities throughout the duration of the disease. However, recent epidemiological data have revealed a decrease in excess mortality, which may be mostly due to the use of cardiovascular drugs. This article deals with present and possible future therapeutic options.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Epoprostenol / therapeutic use*
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / etiology
  • Lung Diseases, Interstitial / physiopathology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prognosis
  • Scleroderma, Systemic* / classification
  • Scleroderma, Systemic* / drug therapy
  • Scleroderma, Systemic* / physiopathology


  • Angiotensin-Converting Enzyme Inhibitors
  • Platelet Aggregation Inhibitors
  • Epoprostenol